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Abstract
Introduction: Critically ill patients with chronic obstructive respiratory diseases (CORD) who require intensive care
unit (ICU) admission are at particular risk for invasive bronchial-pulmonary aspergillosis (IBPA). The purpose of this
study is to investigate clinical features for rapid recognition of IBPA in critically ill patients with CORD.
Methods: We included 55 consecutive CORD patients in a respiratory ICU in a prospective, single-center, cohort
study. In this study, IBPA combined two entities: ATB and IPA.
Results: Thirteen of 55 patients were diagnosed with IBPA. Before ICU admission, three variables were independent
predictors of IBPA with statistical significance: more than three kinds of antibiotics used before the ICU admission,
accumulated doses of corticosteroids (>350 mg) received before the ICU admission, and APACHE II scores >18 (OR,
1.208; P = 0.022; OR, 8.661; P = 0.038; and OR, 19.488; P = 0.008, respectively). After ICU admission, more IBPA patients
had a high fever (>38.5°C) (46.2% versus 11.9%; P = 0.021), wheeze without exertion (84.6% versus 50.0%; P = 0.027),
dry rales (84.6% versus 40.4%; P = 0.005), higher white blood cell counts (21 × 10
9/L versus 9.4 × 10
9/L; P = 0.012),
lower mean arterial pressures (77.9 mm Hg versus 90.5 mm Hg; P = 0.019), and serum creatinine clearances (36.2 ml/
min versus 68.8 ml/min; P < 0.001), and liver-function and coagulation abnormalities. Bronchospasm, sputum
ropiness, and plaque formation were more common for IBPA patients during bronchoscopy (66.7% versus 14.3%; P =
0.082; 18% versus 0; P = 0.169; and 73% versus 13%; P = 0.003, respectively). More IBPA patients had nodules and
patchiness on chest radiograph on day 1 of admission, which rapidly progressed to consolidation on day 7. IBPA
mortality was higher than that of non-IBPA patients (69.2% versus 16.7%; P = 0.001).
Conclusions: IBPA may be suspected in critically ill CORD patients with respiratory failure and clinical and
bronchoscopic manifestations of severe infection, bronchospasm, and rapid progression of radiologic lesions that
are irresponsive to steroids and antibiotics. To avoid misdiagnosis and establish the microbiologic etiology, early
bronchoscopy and tight radiologic follow-up should be performed.
Introduction
Aspergillus tracheobronchitis (ATB) and invasive pulmon-
ary aspergillosis (IPA) are two clinical presentations of
invasive aspergillosis (IA) [1]. The predisposing factors for
ATB and IPA are similar [1,2]. Neutropenic and
immunocompromised patients are particularly at risk.
Chronic obstructive respiratory disease (CORD) is defined
as chronic obstructive diseases of the airways and pulmon-
ary tissues. CORD includes a wide array of serious dis-
eases, and chronic obstructive pulmonary disease (COPD),
bronchial asthma, and bronchiectasis are common CORDs
[3]. Patients with CORD frequently experience acute
exacerbations of their underlying illnesses that require
hospitalization or intensive care unit (ICU) admission.
Recent reports suggest that the incidence of IA appears to
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[4-6]. Moreover, CORD was a major component of criti-
cally ill patients with IA in the ICU. Despite invasive venti-
lation and antifungal treatments, the mortality due to IPA
for critically ill COPD patients remains at 67% to 100%
[2,6-10], and the mortality for ATB is 80% [2].
These high mortality rates may be the result of unclear
clinical features and the delayed diagnoses and treat-
ments for ATB and IPA among CORD patients. Recently,
Tasci et al. [2] described the clinical features of ATB and
proposed an optimal diagnostic strategy. Bulpa et al.[ 7 ]
proposed a series of diagnostic criteria for IPA in the
COPD population, which provided the criteria for the
clinical diagnosis of IPA and ATB. However, these results
were based on retrospective studies [2,7].
Several reports have suggested that ATB might pro-
gress to or coexist with IPA [11,12]. A recent study
showed that ATB could occur in moderately or non-
immunocompromised patients with impaired airway
structures or defense functions and may be an early
stage of IPA [13]. ATB and IPA might be two phases or
manifestations of one entity, invasive bronchial-pulmon-
ary aspergillosis (IBPA), which was rarely recognized
before. In the present study, we preferred to combine
IPA and ATB as one disease, and we used the term
IBPA to indicate these two subentities.
The aim of this single-center prospective cohort study
was to describe the early clinical signs and to evaluate
the available diagnostic procedures for IBPA in critically
ill CORD patients in our ICU to assess their importance
for rapid recognition and appropriate treatment.
Materials and methods
Study population and data collection
In our study, all of the patients were admitted to an ICU
because of respiratory failure from February 2007 to
November 2008. These patients were older than 18
years and had been diagnosed with either severe COPD,
stage III or IV according to the Global Initiative for
Chronic Obstructive Lung Disease (GOLD), moderate
or severe persistent bronchial asthma according to Glo-
bal Initiative for Asthma (GINA), or bronchiectasis with
respiratory failure according to their clinical history,
symptoms, signs, and laboratory findings.
The following information was stored in a data file:
patients’ characteristics, including age, sex, medical his-
tory, and reasons for ICU admission; use of immuno-
suppressive drugs (steroids and others) and antibiotics;
presence of typical symptoms and signs; and standard
ICU laboratory findings on days 1, 4, and 7 after admis-
sion, including complete blood count, arterial blood gas
analysis (ABGA), serum biochemistry tests, activated
partial thromboplastin time (APTT), and microbiologic
examination; and disease severity, assessed according to
the Acute Physiology and Chronic Health Evaluation II
(APACHE II) on their admission to the ICU.
A sandwich enzyme-linked immunosorbent assay (ELISA)
for galactomannan (GM) detection (Platelia Aspergillus;
Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France)
was used according to the manufacturer’s instructions.
Serum sampling for GM detection was done on days 1, 4,
and 7 after ICU admission. An optical density (OD) ratio of
0.5 or greater for GM in serum was considered positive.
Fiberoptic bronchoscopy with bronchoalveolar lavage
was performed on days 1, 4, and 7 of inclusion if the
patient was intubated and if feasible. The selection of
sampling areas was based on the infiltrate location on a
chest radiograph. The presence of any tracheal or bron-
chial lesions was recorded by the endoscopist (QZ).
Lavage samples were submitted for direct microscopic
examination and bacterial and fungal cultures.
A chest radiograph (CXR) by bedside was done on
days 1, 4, and 7 after ICU admission. Pulmonary com-
puted tomography (CT) was also done if feasible,
depending on the patients’ situations.
Antifungal treatment was started and selected at the
discretion of the attending physician (QZ) and was not
protocol defined.
The study was approved by the ethics committee, and
written, informed consents were obtained from the
patients or their next of kin.
Processing of clinical samples
LRT samples of all patients included in this study were
taken once a day for the first 3 days of their ICU stays.
LRT samples were collected again once per week if the
patient remained in the ICU for more than 7 days. All
LRT specimens were cultured on conventional media,
including sheep-blood agar and chocolate agar. At the
same time, all LRT specimens were cultured on CHRO-
Magar medium and Sabouraud dextrose agar. Cultures
were incubated at 25°C and 37°C, respectively, for 7 to
14 days. When spore growth was suboptimal on the
routine media, LRT samples were further cultured on
potato dextrose agar for a better conidial production.
Aspergillus isolates were identified by using standard
morphologic procedures, including colonial morphology,
growth velocity, color, morphology of hyphae, and char-
acteristics of hyphae and spores under microscopy.
Case definitions of IBPA
According to the definitions of invasive fungal disease of
the European Organization for Research and Treatment
of Cancer/Mycoses Study Group (EORTC/MSG), ATB
is diagnosed when tracheobronchial ulceration, nodule,
pseudomembrane, plaque, or eschar is seen on broncho-
scopic analysis, which is confirmed by biopsy or positive
culture for Aspergillus or both [1].
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ble,” based on case definitions of EORTC/MSG [1]. Pro-
ven IPA referred to histopathologic evidence of tissue
invasion by septated, acutely branching filamentous
fungi together with a positive culture. Probable IPA
referred to the presence of a positive culture or cytology
for Aspergillus species from any lower respiratory tract
(LRT) sample together with one major criterion (halo
sign, air-crescent sign, or cavity within an area of conso-
lidation on CT scan) or two of three minor clinical cri-
teria (symptoms of LRT infection, pleural rub, or new
infiltrate without an alternative diagnosis). Possible
infection referred to patients who fulfilled probable
infection criteria but did not have a positive Aspergillus
culture or microscopy from LRT, or serology. Patients
with positive cultures for Aspergillus from nonsterile
sites, but without any other evidence of fungal infection,
were considered to be colonized. Diagnosis was not
based on a serum GM test.
The diagnosis of IBPA referred to a patient diagnosed
with ATB or IPA or both. Patients diagnosed with ATB
or IPA or both were included in the IBPA group.
Among critically ill patients with COPD, bronchial
asthma, and bronchiectasis, those diagnosed as non-
IBPA were included in the non-IBPA group. Patients
with Aspergillus colonization were considered nonin-
fected cases and were included in the non-IBPA group.
Statistical analysis
Patients with CORD admitted to the ICU were divided
into IBPA and non-IBPA groups. The clinical signs and
results of diagnostic tests were compared between the
two groups. Normally distributed continuous variables
were expressed as mean ± SD and compared with a t
test. Non-normally distributed continuous variables
were expressed as median and quartiles and compared
with the Wilcoxon rank-sum test. Categoric variables
were compared with a c
2 test. Multivariate logistic-
regression analysis was used to identify independent risk
factors for IBPA patients. The P values < 0.05 were con-
sidered significant. All analyses were carried out with
the use of SPSS software for Windows (release 11.5).
Results
Patient characteristics
From February 2007 to November 2008, in total, 343
patients were admitted to our ICU. Fifty-five of these
patients who met the inclusion criteria were enrolled: 47
(86%) had COPD, four (7%) had asthma, and four (7%)
had bronchiectasis. The characteristics of the total study
group are shown in Table 1.
Thirteen (24%) patients were diagnosed with IBPA, and
the remaining patients (42) did not have IBPA. In IBPA
group, 11 patients had COPD, one patient had asthma,
and one patient had bronchiectasis. According to the
diagnostic criteria for IBPA, the 13 IBPA patients were
classified as proven (n = 4), probable (n = 8), and possible
IBPA (n =1 )( T a b l e2 ) .O n ec a s ew a sd i a g n o s e da sc o l o -
nized. Aspergillus spp. was the only mold pathogen, and
no other non-Aspergillus invasive mold infection was
found in the patients studied. IBPA cases were diagnosed
at a median of 2 days (IQR, 1 to 7 days) after the patients’
admission to the ICU. The reasons for respiratory failure
in IBPA patients were infection (12 cases) and heart dys-
function (one case), which caused exacerbations of their
underlying respiratory diseases. Eleven of the 13 IBPA
patients had a positive culture or microscopic examina-
tion of Aspergillus spp. for their LRT samples collected at
the first day of their ICU admission, and two patients had
positive microbiologic results for LRT samples collected
at day 6 and 8 after the ICU admission. As a result, these
11 cases were determined as having developed the infec-
tion before the ICU admission. All IBPA patients and 25
non-IBPA patients received invasive mechanical ventila-
tion (100% versus 59.5%; P = 0.016). The duration of
invasive mechanical ventilation for IBPA was significantly
longer than that for non-IBPA patients (8 days versus 3
days; P = 0.006). The mortality for IBPA was higher than
that of control group (69.2% versus 16.7%; P =0 . 0 0 1 ) .
The causes of death for these nine IBPA patients were
multiple organ failure for four cases, acute renal failure
for three cases, and septic shock for two cases.
Four patients had tracheobronchial mucus biopsies,
and two of them had lung biopsies; no autopsy was
obtained for this study.
In the IBPA group, 13 patients had a length of ICU stay
of more than 1 day, 12 patients for more than 4 days, and
9 patients for more than 7 days, respectively. In the non-
IBPA patients, 42 cases, 36 cases, and 23 cases stayed in
the ICU for more than 1, 4, and 7 days, respectively.
Steroids and antibiotics
Steroids
The dosages of systemic steroids received by all
patients were converted to prednisone or equivalent
doses by steroid potency (for example, 20 mg of
hydrocortisone = 5 mg of prednisone). The numbers
of patients who received steroids treatment before ICU
admission in the IBPA and non-IBPA groups were
similar (69% versus 62%). Compared with non-IBPA
patients, before their admissions to the ICU, IBPA
patients received a significantly higher mean dosage of
systemic steroids (371 mg versus 180 mg of prednisone
or equivalent; P = 0.006). IBPA patients received ster-
oids for a longer period than did non-IBPA patients
(median, 6 days versus 1 day). The median daily
dosages of systemic steroids received by IBPA and
non-IBPA patients were similar (Table 1).
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Most patients in the two groups received antibiotics treat-
ment before their ICU admissions. The IBPA patients were
given significantly more kinds of antibiotics for a longer
treatment period than were the non-IBPA patients (Table 1).
Symptoms and Signs
Symptoms
More IBPA patients had high fevers did non-IBPA
patients (T >38°C; 46% versus 12%; P = 0.021). Com-
pared with non-IBPA patients, wheeze without exertion
was a more common symptom for IBPA patients (85%
versus 50%). Hemoptysis and chest pain were rare in
both groups (Table 3).
Signs
On admission to the ICU, heart rates and respiratory
rates were similar for IBPA and non-IBPA patients.
Mean arterial blood pressures were significantly lower
for IBPA patients than for non-IBPA patients (78 mm
Hg versus 91 mm Hg; P = 0.019). Dry rales were heard
more frequently in the lungs of IBPA patients (85% ver-
sus 40%; P = 0.005) (Table 3).
Multivariate analysis
Variables with a P value < 0.1 in the univariate analysis
are shown in Tables 1 and 3. Of these, three were
included in the multivariate model: more than three
kinds of antibiotics used before the ICU admission,
Table 1 Patient characteristics
IBPA Control P value
Number of patients 13 42 ——
Demographic characteristics
Age, mean, years (SD) 74.3 (13.5) 73.2 (7.46) 0.150
Sex, number (%)
Male 7 (53.8) 25 (59.5) 0.228
Female 6 (46.2) 17 (40.5)
Length of hospitalization before ICU admission, days (IQR) 15 (8.5-29.5) 3 (2-6.25) 0.001
a
Length of ICU stay, days (IQR) 10 (6-20) 7 (5-14) 0.253
Transferred from other hospital/ICU, number (%) 5 (38.5) 5 (11.9) 0.079
From other ICU, number (%) 1 (7.7) 3 (7.1) 0.672
From other hospital, number (%) 4 (30.8) 2 (4.8) 0.034
a
Medical history, number (%)
Three or more hospitalizations 9 (69.2) 38 (90.5) 0.147
Chronic renal dysfunction 3 (23.1) 4 (9.5) 0.421
Diabetes mellitus 0 (0) 6 (14.3) 0.350
Nonhematologic malignancy 0 (0) 3 (7.1) 0.438
Corticosteroids use
Number of patients with steroids use (%) 9 (69.2) 26 (61.9) 0.881
Prolonged steroids for≥3 weeks before ICU admission, number (%) 1 (7.7) 5 (11.9) 1.000
Accumulated dosage of systemic steroids,▵ mg, mean (SD) 371 (199) 180 (150) 0.006
a
Accumulated dosage of systemic steroids,▵ mg, median (IQR) 400 (190-535) 105 (75-241) 0.021
a
Duration of steroids before ICU admission, day, median (IQR) 6 (0-7) 1 (0-3) 0.041
a
Daily dosage of systemic steroids ▵, mg, median (IQR) 50 (0-75) 50 (0-63) 0.377
Inhaled steroids, number (%) 1 (7.7) 2 (4.8) 1.000
Antibiotics
Number of patients with antibiotics (%) 13 (100) 36 (85.7) 0.350
Number of kinds of antibiotics, median (IQR) 3 (1-5) 2 (1-2) 0.037
a
Length of antibiotics use, days, median (IQR) 10 (4.5-22.0) 3 (2-10.3) 0.015
a
APACHE II scores, mean (SD) 18.6 (7.1) 12.6 (4.5) 0.010
a
Mechanical ventilation
Total number of patients with invasive ventilation during RICU stays (%) 13 (100) 25 (59.5) 0.016
a
Duration of invasive mechanical ventilation, days, median (IQR) 8 (5-15) 3 (0-10) 0.006
a
Outcome, number (%)
Survival 4 (30.8) 35 (83.3) 0.001
a
Dead 9 (69.2) 7 (16.7)
SD, standard deviation; IQR, interquartile range; APACHE II, Acute Physiology and Chronic Health Evaluation II. ▵The steroid doses were converted to prednisone
dose (for example, 20 mg of hydrocortisone = approximately 5 mg of prednisone).
aP < 0.05.
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Page 5 of 12accumulated doses of corticosteroids (>350 mg) received
before the ICU admission, and APACHE II scores >18.
The multivariate analysis selected the three variables
with independent statistical significance (Table 4).
Laboratory tests
White blood cell (WBC) counts were significantly
higher for IBPA patients on days 1, 4, and 7 of ICU
admission. The pH and base excess (BE) were signifi-
cantly lower for IBPA patients on the first day, but
were not different on days 4 and 7. Serum creatinine
clearances were significantly decreased for IBPA com-
pared with non-IBPA patients on days 1, 4, and 7 of
ICU admission. During their ICU stays, IBPA patients
had significantly higher serum aspartate aminotrans-
ferase levels, alanine aminotransferase levels, and acti-
vated partial thromboplastin times (see Table 5, Figure
S1 in Additional file 1, and Figure S2 in Additional
file 2).
Fiberoptic bronchoscopy
On days 1, 4, and 7 after ICU admission, 11, 10, and
four IBPA patients and 15, six, and three non-IBPA
patients had bronchoscope examinations, respectively.
For IBPA patients, mucous hyperemia and edema were
observed, ropy sputum was difficult to suck out, and
four cases showed pseudomembrane formation under
bronchoscopic analysis. Bronchospasm, plug formation
and sputum ropiness were more common for IBPA on
the first day after ICU admission (66.7% versus 14.3%;
P = 0.082; 18% versus 0; P = 0.169; and 73% versus 13%;
P = 0.003, respectively). Four patients in the IBPA
group had biopsies of the tracheobronchial tree during
bronchoscopy, which showed Aspergillus invasion into
the tracheobronchial wall.
Radiologic examination
On days 1, 4, and 7 after ICU admission, 13, 12, and
nine IBPA patients and 42, 32, and 22 non-IBPA
Table 3 Clinical characteristics (symptoms and signs)
IBPA Control P value
Number of patients 13 42 ——
Symptoms, number (%)
Fever 8 (61.5) 10 (23.8) 0.028
a
Body temperature >38.5°C 6 (46.2) 5 (11.9) 0.021
a
Cough 10 (76.9) 36 (85.7) 0.749
Wheeze 11 (84.6) 36 (85.7) 1.000
Wheeze with exertion 0 (0) 15 (35.7) 0.030
a
Wheeze without exertion 11 (84.6) 21 (50) 0.027
a
Sputum production 10 (76.9) 37 (88.1) 0.583
Phlegm 3 (23.1) 5 (11.9) 0.583
Hemoptysis 2 (15.4) 1 (2.4) 0.136
Chest pain 2 (15.4) 2 (4.8) 0.234
Signs at ICU admission
Body temperature, °C, mean (SD) 36.6 (0.5) 36.7 (0.6) 0.876
Heart rate, beats per minute, mean (SD) 106.5 (23.9) 95.2 (21.2) 0.108
Respiratory rate, breaths per minute, mean (SD) 28.3 (8.5) 24.3 (11.4) 0.243
Mean arterial pressure, mean (SD) 77.9 (14.2) 90.5 (17.0) 0.019
a
Rales, number (%)
Dry rales 11 (84.6) 17 (40.4) 0.005
a
Moist rales 9 (69.2) 30 (71.4) 1.000
SD, standard deviation; IQR, interquartile range.
aP < 0.05.
Table 4 Variables selected for prediction of invasive bronchopulmonary aspergillosis by multivariate logistic
regression analysis in patients with chronic obstructive respiratory disease
Wald P Value Odds ratio 95% Confidence interval
Inferior Superior
Accumulated dosage of systemic steroids (>350 mg) received before the ICU admission 4.326 0.038 8.661 1.133 66.239
More than three kinds of antibiotics before the ICU admission 5.211 0.022 1.208 1.027 1.422
APACHE II scores >18 6.974 0.008 19.488 2.150 176.613
Constant 11.912 0.001
APACHE, Acute Physiology and Chronic Health Evaluation; ICU, intensive care unit.
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Page 6 of 12patients had radiologic examinations, respectively. In
each group, six patients had chest CTs on the first day of
ICU admission. Among the six cases with IBPA, one had
a halo sign, and one had a cavity on the CT scans. The
CT scans of the other four IBPA cases and the six non-
IBPA patients showed nonspecific patching, nodules, and
consolidations. The numbers of IBPA patients with
nodules and consolidations on CXR increased rapidly
from day 1 to day 7 of ICU admission (nodules: from
three patients to six patients; consolidations: from one
patient to five patients). Compared with non-IBPA
patients, patchiness and nodules were more common on
CXR on day 1 of admission for IBPA patients (77% versus
43%, P = 0.032; and 23% versus 2.3%, P = 0.012, respec-
tively). At day 4, no significant differences were found
between the two groups, and at day 7, nodules and con-
solidations were significantly more common for the IBPA
patients (60% versus 9%, P = 0.002; and 50% versus 14%,
P = 0.028) (see Figure S3 in Additional file 3).
Serum GM test
The sensitivities, specificities, positive and negative pre-
dictive values, and total consistent rates for positive GM
results of a first test and of a second test, at least one
positive GM result from two consecutive tests, and both
positive GM results of two consecutive tests are shown
in Table 6. The total consistent rates did not show sig-
nificant differences between different diagnostic
strategies.
Diagnostic algorithm
Based on the risk factors, symptoms and signs, and diag-
nostic procedures evaluated in our study, a diagnostic
algorithm is shown in Figure 1.
Discussion
The main strength of our study is its prospective design
that included non-IBPA CORD patients as a control
group. This enabled us to discriminate between IBPA in
the CORD population and acute exacerbations caused
by CORD itself. Our study revealed that before ICU
admission, three variables were independent predictors
of IBPA: more than three kinds of antibiotics used
before the ICU admission, accumulated doses of corti-
costeroids (>350 mg) received before the ICU admission,
and APACHE II scores >18. In critically ill CORD
Table 5 Laboratory findings
Day of ICU admission IBPA Control P value
Complete blood count
White blood cell count (×10
9/L), mean (SD) Day 1 21.0(14.0) 9.4(3.7) 0.012
a
Day 4 17.5(5.6) 10.6(13.9) 0.101
Day 7 19.5(6.3) 10.0(5.4) 0.000
a
Neutrophilic granulocyte (%), mean (SD) Day 1 90.2(6.3) 84.3(10.0) 0.053
Day 4 89.4(7.7) 79.3(10.7) 0.004
a
Day 7 87.8(6.9) 80.3(8.6) 0.027
a
Arterial blood gas analysis
pH, mean (SD) Day 1 7.25(0.14) 7.36(0.11) 0.005
a
Day 4 7.42(0.08) 7.42(0.05) 0.768
Day 7 7.42(0.10) 7.42(0.05) 0.995
PaCO2 (mm Hg), mean (SD) Day 1 65.3(36.1) 68.8(33.1) 0.745
Day 4 53.3(22.7) 53.5(11.4) 0.979
Day 7 47.9(22.4) 49.2(12.9) 0.845
Ratio of the PaO2 to FiO2, mean (SD) Day 1 166.0(86.8) 219.1(128.8) 0.171
Day 4 197.5(80.0) 225.7(88.2) 0.332
Day 7 199.9(72.3) 236.8(83.8) 0.255
Renal function
Clearance of creatinine (ml/min), mean (SD) Day 1 36.2(20.4) 68.8(27.5) 0.000
a
Day 4 36.6(24.0) 82.5(51.5) 0.005
a
Day 7 33.3(32.3) 77.6(50.4) 0.021
a
Liver function
ALT (U/L), median (IQR) 52.5(36.5-95) 28(20-43) 0.003
a
AST (U/L), median (IQR) 67(49-118.5) 26.5(21.8-49.8) 0.000
a
Coagulation
APTT (s), median (IQR) 34.8(28.4-49.3) 28.5(26.2-37.7) 0.046
a
ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; FiO2, the fraction of inspired oxygen; SD, standard
deviation; IQR, interquartile range; PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen.
aP < 0.05.
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Page 7 of 12patients, IBPA may present as respiratory failure and
clinical and bronchoscopic manifestations of severe
infection, bronchospasm, and rapid progression of radi-
ologic lesions that are unresponsive to steroids and
antibiotics.
In CORD patients, because the structures and defense
functions of the airways and lung parenchyma are
damaged by their underlying respiratory diseases,
Aspergillus may colonize in these sites. During the early
period of invasive aspergillosis, infection may be limited
to the tracheobronchial tree, presenting as ATB. This
may account for the obvious bronchospasm without
radiologic appearance in some cases during the early
phase of infection. With corticosteroids and broad-spec-
trum antibiotics therapy, the infection could spread to
the distal airways and lung parenchyma, presenting as
Table 6 Results of first and two consecutive detections of galactomannan in serum of critically ill CORD patients
Single GM detection (95% CI) Two consecutive GM detections (95% CI) (n = 48)
Positive for a first test
(n = 55)
Positive for a second test
(n = 48)
At least one positive of the two
consecutive tests
Both positive for the two
consecutive tests
Sensitivity
(%)
46.2 (33.3-59.1) 50.0 (35.9-54.1) 53.8 (39.7-67.9) 41.7 (27.8-55.6)
Specificity
(%)
83.3 (73.4-93.2) 93.5 (86.5-100) 81.0 (69.9-92.1) 93.5 (86.5-100)
PPV (%) 46.2 (33.3-59.1) 75.0 (62.7-87.3) 46.7 (32.6-60.8) 71.4 (58.7-84.1)
NPV (%) 83.3 (73.4-93.2) 82.9 (72.2-93.6) 85.0 (74.9-95.1) 80.6 (69.7-91.5)
TCR (%) 74.5 (63.0-86.0) 81.4 (70.4-91.4) 74.5 (62.2-86.8) 79.1 (67.9-90.3)
CORD, chronic obstructive respiratory disease; NPV, negative predictive value; PPV, positive predictive value; TCR, total consistent rate.
Figure 1 Diagnostic algorithm based on patient’s clinical features and diagnostic procedures for IBPA in critically ill CORD patients
admitted in ICU. *Resistant to appropriate treatment including corticosteroids and antibiotics.
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Page 8 of 12IPA. Several reports have shown that lung parenchyma
was usually involved together with ATB, and invasive
ATB may indicate an advanced pulmonary lesion caused
by Aspergillus [11-15]. In our study, two patients who
had a tracheobronchial mucus and lung biopsy (cases 2
and 12) had specific radiologic findings on their CT
scans, as well as positive GM tests. In addition, in case
2, the lesions of the airways and lung parenchyma
responded to antifungal treatment, which suggested a
concomitant pulmonary lesion secondary to Aspergillus
( s e eF i g u r e2 ) .T h e r e f o r e ,A T Bm a yb ea ne a r l ys t a g eo f
IPA, and may exist either before or with IPA.
For CORD patients, corticosteroids treatment is con-
sidered to be an important risk factor for IBPA
[4,7,10,16]. The conicidal activity of human tissue
macrophages is responsible for the monocyte-mediated
damage to fungal hyphae [17], and this immune func-
tion could be impaired by corticosteroids [18]. More-
over, corticosteroids promote the in vitro growth of
Aspergillus fumigatus [19]. Previous studies reported
that COPD patients who were given an average daily
dose of systemic corticosteroids greater than 73 to 80
mg of prednisone (or equivalent), and with an average
therapy duration of 29.7 days to 2 months were prone
to developing invasive aspergillosis [6,8,20]. However,
another retrospective study showed that an accumulated
dosage of steroids equivalent to >700 mg of prednisone
received during the 3 months before hospital admission
Figure 2 Radiologic, bronchoscopic, and histologic information of Patient IBPA Case 2. (a) Chest x-ray shows patchings and multiple
nodules in bilateral lungs, with severe barotrauma. (b) Chest HRCT shows patchings and multiple nodules with halo sign in bilateral lungs. (c)
Bronchoscopy shows inflammation and white plaques formation of the airway. (d) Histologic examination of biopsy specimen from lung tissue
shows many Aspergillus hyphae invading the lung parenchyma.
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Page 9 of 12may be a risk factor for IPA in COPD patients [21]. In
our study, the patients in the IBPA and non-IBPA
groups received the same daily dosages of steroids.
However, because the IBPA patients received them for a
longer period (median, 6 days versus 1 day), the accu-
mulated steroid dosages in this group may have been
higher than those in the non-IBPA group. According to
the multivariate analysis in our study, an accumulated
dosage of 350 mg prednisone may be associated with
IBPA in critically ill CORD patients. For the two IBPA
patients who had positive microbiologic results for LRT
samples collected at days 6 and 8 after the ICU admis-
sion, no corticosteroids were used after their ICU
admission, which means that for the 13 IBPA cases, the
“accumulated dosage before the admission to the ICU”
was the same as “accumulated dose of corticosteroids
before the first isolation of Aspergillus“ proposed in a
previous study [21].
Antibiotic therapy before admission to an ICU could
also be an important risk factor. This was observed, but
not confirmed, in two retrospective studies [8,22].
Muquim et al. [20] reported that IPA that occurred
with COPD was associated with the use of multiple
broad-spectrum antibiotics before patients’ hospitaliza-
tions, and the risk for IPA increased with the number of
antibiotics used. The number of antibiotics used may
suggest a pneumonia that did not respond to several
antibiotic treatments. In our study, a median of three or
more antibiotics for 10 days may have been a risk factor
for IBPA for the critically ill CORD patients before their
ICU admissions.
CORD patients are not immunocompromised,
a l t h o u g hs o m eo ft h e mm a yb em i l d l yi m m u n o s u p -
pressed. Therefore, when their airways or lung par-
enchyma are invaded by Aspergillus, their immune
systems should react to this pathogen, and they may
show a severe systemic inflammatory reaction [7] and
obvious bronchospasm [23]. High fever (T >38.5°C)
a n de l e v a t e dW B C( > 2 0×1 0
9/L) are systemic manifes-
tations of inflammatory reactions. The trend of low
arterial pressure, acidosis, acute renal dysfunction
(creatinine clearance <36 ml/min), and abnormalities
of liver function and coagulation in critically ill CORD
patients may suggest the presence of a more severe
inflammatory status, such as septic shock and multior-
gan dysfunction, which are the main causes of death
for IBPA patients. Dyspnea without exertion and dif-
fuse wheezing rales in the lungs are manifestations of
severe bronchospasm, which may suggest a local
inflammatory status of the airways. The presentation
of severe inflammatory status and bronchospasm are
not specific for IBPA; however, when they are resistant
to appropriate antibiotics and corticosteroids, a diag-
nosis of IBPA should be suspected.
A local inflammatory reaction can also be observed
directly during bronchoscopy, presenting as mucous
hyperemia, edema, large amounts of ropy airway secre-
tions, plaque, pseudomembrane formation, and bronch-
o s p a s m .F u r t h e r ,p e r f o r m i n gb r o n c h o s c o p yw i t h
microscopic examinations of tracheal or bronchial speci-
mens is the most sensitive diagnostic test for an early
diagnosis and treatment of ATB [2]. In our study, four
patients had ATB presentations during bronchoscopic
analysis, and all of them were confirmed as proven ATB
with biopsies of tracheobronchial tissues. A previous
study suggested that when IPA is suspected, but culture
evaluations of nonbronchoscopic samples alone are
negative, intubation and bronchoscopy should be con-
sidered [8]. Therefore, bronchoscopy is necessary for
establishing an early diagnosis of ATB.
Risks exist for ICU patients in having chest CTs
because of their severe conditions and difficulties with
transportation. As a result, radiologic data for this popu-
lation is mainly dependent on bedside CXR. However,
unlike immunocompromised patients, early findings on
CXR or CT scan for IBPA in CORD patients are non-
specific, and halo signs and cavitations are uncommon
[4,16,20,24]. Moreover, for some ATB patients, no
obvious abnormalities could be found on their chest
images. Therefore, it is difficult to establish an early
diagnosis of IBPA based on classic manifestations on
their chest CTs or CXRs for CORD patients. Further,
our study suggested the rapid progression of patching to
nodules and consolidations in multiple segments and
lobes, which were unresponsive to empiric antibacterial
agents. Therefore, the rapid progression on a chest
image may be suggestive of suspected IBPA.
In our study, a high proportion of IBPA patients had a
positive culture for Aspergillus in the same day (day 1)
of ICU admission (84.6%, 11 of 13). In the 11 cases, no
patients had the diagnosis of IA before their admission,
no Aspergillus was isolated previous to the ICU admis-
sion, and none of these patients received antifungal
agents before ICU admission. It means that, probably,
these patients were admitted to the unit because of the
IA, which can partly explain why the mortality was as
high as 69% in our study.
We realize that this study has limitations. First, to per-
form multivariate analysis on a small dataset (three pre-
dictor variables for 13 IBPA cases) was prone to bias
and model overfitting, yielding spurious findings, which
made a large 95% CI for OR in our analysis. Increasing
t h es a m p l es i z ea n dc o l l e c t i n gm o r eI B P Ac a s e si na
further study may avoid this kind of limitation. Second,
only four patients had biopsies and were diagnosed as
having proven IBPA, which may cause possible misclas-
sification bias. Finally, this is a single-center study, in
which a setting may have tremendous overuse of
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Page 10 of 12antibiotic agents for empiric treatment and prophylaxis.
A multicenter prospective study maybe needed in the
future to avoid this kind of limitation.
Conclusions
In conclusion, IBPA is not rare among critically ill
CORD patients with ICU admissions, with mortality as
high as 69%. IBPA may be suspected in critically ill
CORD patients with respiratory failure and clinical and
bronchoscopic manifestations of severe infection (high
fever, elevated WBC count, low blood pressure and mul-
tiorgan dysfunction, sputum ropiness, and plaque forma-
tion), bronchospasm (wheeze and dry rales), and rapid
progression of radiologic lesions, which are irresponsive
to steroids and antibiotics. To avoid misdiagnosis and to
establish the microbiologic etiology, early bronchoscopy
and tight radiologic follow-up should be performed.
Key messages
￿ ATB may be an early stage of IPA and may exist
either before or with IPA. Therefore, ATB and IPA
might be two phases or manifestations of one entity,
invasive bronchopulmonary aspergillosis (IBPA).
￿ In critically ill CORD patients, before ICU admis-
sion, three variables were independent predictors of
IBPA: more than three kinds of antibiotics used
before the ICU admission, accumulated doses of cor-
ticosteroids (>350 mg) received before the ICU
admission, and APACHE II scores >18.
￿ In critically ill CORD patients, IBPA may present
as respiratory failure and clinical and bronchoscopic
manifestations of severe infection, bronchospasm,
and rapid progression of radiologic lesions that are
irresponsive to steroids and antibiotics.
￿ IBPA is not rare among critically ill CORD patients
with ICU admissions, with mortality as high as 69%.
Additional material
Additional file 1: Figure S1. Arterial blood gas analysis and blood cell
count after RICU admission.
Additional file 2: Figure S2. Biochemical and coagulation test after
RICU admission.
Additional file 3: Figure S3. Comparison of the chest radiologic
presentation between the two groups.
Abbreviations
ABGA: arterial blood gas analysis; APACHE II: the Acute Physiology and
Chronic Health Evaluation II; APTT: activated partial thromboplastin time;
ATB: Aspergillus tracheobronchitis; BE: base excess; COPD: chronic obstructive
pulmonary disease; CORD: chronic obstructive respiratory disease; CT:
computed tomography; CXR: chest x-ray; EORTC/MSG: the European
Organization for Research and Treatment of Cancer/Mycoses Study Group;
GM: galactomannan; IA: invasive aspergillosis; IBPA: invasive bronchial-
pulmonary aspergillosis; ICU: intensive care unit; IPA: invasive pulmonary
aspergillosis; LRT: lower respiratory tract; WBC: white blood cell.
Acknowledgements
We acknowledge the efforts of Dr. Lirong Liang for her statistical support.
Written consent for publication was obtained from patient case no. 2 of
IBPA.
Author details
1Department of Respiratory and Critical Care Medicine, Beijing Institute of
Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University,
8 Gongren Tiyuchang South Road, Beijing, 100020, PR China.
2Department of
Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory
Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren
Tiyuchang South Road, Beijing, 100020, PR China.
Authors’ contributions
All authors made substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data; reviewed and
approved the final manuscript; and contributed significantly to this study.
Drs HH and LD contributed equally to the work. QZ takes full responsibility
for the integrity of the submission and publication and was involved in
study design. HH had full access to all the data in the study, takes
responsibility for the integrity of the data and the accuracy of the data
analysis, and was responsible for the data verification, analysis, and drafting
of the manuscript. LD had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data
analysis. FL was responsible for the microbiologic examination and the data
collection.
Competing interests
The authors declare that they have no competing interests.
Received: 8 September 2010 Revised: 30 November 2010
Accepted: 6 January 2011 Published: 6 January 2011
References
1. Pauw BD, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T, Pappas P,
Maertens J, Lortholary O, Kauffman C, Denning D, Patterson T,
Maschmeyer G, Bille J, Dismukes W, Herbrecht R, Hope W, Kibbler C,
Kullberg B, Marr K, Munoz P, Odds F, Perfect J, Restrepo A, Ruhnke M,
Segal B, Sobel J, Sorrell T, Viscoli C, Wingard J, et al: Revised definitions of
invasive fungal disease from the European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections Cooperative Group
and the National Institute of Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008,
46:1813-1821.
2. Tasci S, Glasmacher A, Lentini S, Tschubel K, Ewig S, Molitor E, Sauerbruch T,
Luderitz B, Rabe C: Pseudomembranous and obstructive Aspergillus
tracheobronchitis: optimal diagnostic strategy and outcome. Mycoses
2006, 49:37-42.
3. Bousquet J, Dahl R, Khaltaev N: Global Alliance against Chronic
Respiratory Diseases. Eur Respir J 2007, 29:233-239.
4. Pittet D, Huguenin T, Dharan S, Sztajzel-Boissard J, Ducel G, Thorens J,
Auckenthaler R, Chevrolet J: Unusual cause of lethal pulmonary
aspergillosis in patients with chronic obstructive pulmonary disease. Am
J Respir Crit Care Med 1996, 154:541-544.
5. Crean J, Niederman M, Fein A, Feinsilver S: Rapidly progressive respiratory
failure due to Aspergillus pneumonia: a complication of short-term
corticosteroid therapy. Crit Care Med 1992, 20:148-150.
6. Rello J, Esandi M, Mariscal D, Gallego M, Domingo C, Valles J: Invasive
pulmonary aspergillosis in patients with chronic obstructive pulmonary
disease: report of eight cases and review. Clin Infect Dis 1998,
26:1473-1475.
7. Bulpa P, Dive A, Sibille Y: Invasive pulmonary aspergillosis in patients
with chronic obstructive pulmonary disease. Eur Respir J 2007, 30:782-800.
8. Bulpa P, Dive A, Garrino M, Delos M, Gonzalez M, Evrard P, Glupczynski Y,
Installe E: Chronic obstructive pulmonary disease patients with invasive
pulmonary aspergillosis: benefits of intensive care? Intensive Care Med
2001, 27:59-67.
He et al. Critical Care 2011, 15:R5
http://ccforum.com/content/15/1/R5
Page 11 of 129. Clancy C, Nguyen M: Acute community-acquired pneumonia due to
Aspergillus in presumably immunocompetent hosts: clues for
recognition of a rare but fatal disease. Chest 1998, 114:629-634.
10. Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE,
Wijngaerden EV: Invasive aspergillosis in critically ill patients without
malignancy. Am J Respir Crit Care Med 2004, 170:621-625.
11. Xavier MO, Sales Mda P, Camargo Jde J, Pasqualotto AC, Severo LC:
Aspergillus niger causing tracheobronchitis and invasive pulmonary
aspergillosis in a lung transplant recipient: case report. Rev Soc Bras Med
Trop 2008, 41:200-201.
12. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston NJ,
Stevens DA, Theodore J: Ulcerative tracheobronchitis after lung
transplantation: a new form of invasive aspergillosis. Am Rev Respir Dis
1991, 144:552-556.
13. Wu N, Huang Y, Li Q, Bai C, Huang HD, Yao XP: Isolated invasive
Aspergillus tracheobronchitis: a clinical study of 19 cases. Clin Microbiol
Infect 2010, 16:689-695.
14. Campbell MJ, Clayton YM: Bronchopulmonary aspergillosis: a correlation
of the clinical and laboratory findings in 272 patients investigated for
bronchopulmonary aspergillosis. Am Rev Respir Dis 1964, 89:186-196.
15. Young RC, Bennett JE, Vogel CL, Carbone PP, DeVita VT: Aspergillosis: the
spectrum of the disease in 98 patients. Medicine (Baltimore) 1970,
49:147-173.
16. Garnacho-Montero J, Amaya-Villar R, Ortiz-Leyba C, Leon C, Alvarez-Lerma F,
Nolla-Salas J, Iruretagoyena J, Barcenilla F: Isolation of Aspergillus spp. from
the respiratory tract in critically ill patients: risk factors, clinical
presentation and outcome. Crit Care 2005, 9:R191-R199.
17. Diamond R: Inhibition of monocyte-mediated damage to fungal hyphae
by steroid hormones. J Infect Dis 1983, 147:160.
18. Schaffner A: Therapeutic concentrations of glucocorticoids suppress the
antimicrobial activity of human macrophages without impairing their
responsiveness to gamma interferon. J Clin Invest 1985, 76:1755-1764.
19. Tony TC, Robson GD, Denning DW: Hydrocortisone-enhanced growth of
Aspergillus spp.: implications for pathogenesis. Microbiology 1994,
140:2475-2479.
20. Muquim A, Dial S, Menzies D: Invasive aspergillosis in patients with
chronic obstructive pulmonary diseases. Can Respir J 2005, 12:199-204.
21. Guinea J, Torres-Narbona M, Gijon P, Munoz P, Pozo F, Pelaez T, de
Miguel J, Bouza E: Pulmonary aspergillosis in patients with chronic
obstructive pulmonary disease: incidence, risk factors, and outcome. Clin
Microbiol Infect 2010, 16:870-877.
22. Kaiser L, Huguenin T, Lew P, Chapuis B, Pittet D: Invasive aspergillosis:
clinical features of 35 proven cases at a single institution. Medicine
(Baltimore) 1998, 77:188-192.
23. Samarakoon P, Soubani A: Invasive pulmonary aspergillosis in patients
with COPD: a report of five cases and systematic review of the
literature. Chron Respir Dis 2008, 5:19-21.
24. Zhan Q, He H, Tong Z, Li F, Sun B, Wang C: Clinical features of invasive
pulmonary aspergillosis in critically ill patients with chronic respiratory
diseases. Zhonghua Jie He He Hu Xi Za Zhi 2008, 31:282-286.
doi:10.1186/cc9402
Cite this article as: He et al.: Clinical features of invasive bronchial-
pulmonary aspergillosis in critically ill patients with chronic obstructive
respiratory diseases: a prospective study. Critical Care 2011 15:R5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
He et al. Critical Care 2011, 15:R5
http://ccforum.com/content/15/1/R5
Page 12 of 12